Full methods, including software versions, are available in the Supplementary Note. The data and code are publicly available as described in the data and code availability statements.
Maintenance of human iPSCs
Our research complies with all appropriate ethical regulations. Human iPSCs were derived in previous projects with informed consent from all participants, donors and/or their legal guardian(s). A total of 261 human iPSC lines from 254 European donors were obtained as part of the Sanger HipSci project (http://www.hipsci.org; Cambridgeshire 1 NRES REC Reference 09/H0304/77, HMDMC 14/013), Cardiff IPMAR project (Wales REC 3 Reference 12/WA/0052).19 or commercially from Bioneer (TREM2 KO (BIONi010-C-17) and isogenic control (BIONi010-C)). All lines tested negative for mycoplasma and were characterized for pluripotency by expression of stem cell markers, RNA sequencing, and/or germ layer differentiation. Genomes were analyzed by single nucleotide polymorphism (SNP), exome and/or WGS arrays to detect chromosomal abnormalities and copy number variation and to validate identity. For a list of lines used and the location of available datasets and certificates of analysis, see Supplementary Table 1.
Cells were maintained with vitronectin in E8/10% CloneR at 60–85% confluence. Before final pooling, 6–12 lines were seeded into mini-pools at 40,000 cells per cm.2passed once and frozen after 3 days.
iPSC clustering and microglial differentiation
Microglia were differentiated by embryoid bodies20. Each pool contained between 16 and 72 donors. On day 9, 42 embryoid bodies were transferred to a T75 flask and differentiated into precursors. On days 28–109, precursors were collected for 14 days of microglial differentiation. Cell suspensions were seeded in ITMG medium at 500,000 cells per 6-well plate (Greiner Bio-One, 657160) for scRNA-seq, 3,906,250 cells per T75 flask (Greiner Bio-One, 658170) for migration or 1,126,400 cells per 6-well plate for assays. phagocytosis. The medium was supplemented to double the volume on day 3 or 4 after plating, and subsequent changes of half the medium were made on day 7 and day 10 or 11.
On day 11 of microglial differentiation, cells were treated for 72 h with 20 ng ml−1 IFNγ or 100 ng ml−1 LPS.
iMac differentiation
Floating Precursors Collected for 7 Day iMac Differentiation72 in iMac media.
Sample preparation for scRNA-seq
Day 14 iMGLs were dissociated at 37 °C for ≤30 min with 5 mM EDTA and 4 mg ml−1 lidocaine, soaked in 0.04% BSA/DPBS, filtered and counted. The Chromium Next GEM 5′ v2 and 5′ HT v2 lanes received 17,400 and 115,405 viable cells, respectively, and followed the manufacturer’s processing. Quality-controlled libraries were HiSeq/NovaSeq sequenced at ≥20,000 reads per cell.
Migration testing
Each 6-well Transwell insert received 825,000 iMGL day 14 in 2.7 ml ITMG. After 15 min, 3.168 mL of ITMG with or without 3 nM C5a was added to the lower chamber of the insert. After 6 h, sister wells were fixed in 4% paraformaldehyde and DNA from each membrane surface as well as the wash pellet was extracted with Puregene.
NucBlue-stained inserts were imaged before and after removal of cells from the top surface. Cellpose v.2.0.5 (–diameter 5 –flow_threshold 0 –cellprob_threshold -8) was used to count all nuclei, and CellProfiler v.4.2.1 was used to count migrated nuclei (threshold 0.015 to 1.0). Migration was calculated as the ratio of migrated nuclei to all nuclei, and chemotaxis was defined as C5a.+ minus C5a− report.
Two-color phagocytosis test
SH-SY5Y mCherry-eGFP pmChGIP F4 clone was generated and cultured as previously described20. Precursors (1,126,400 per 6-well plate) were differentiated for 14 days and incubated with fixed SH-SY5Y cargo at a cargo:iMGL ratio of 2:1 for 2 h. Washed cells were detached, fixed in 4% paraformaldehyde, and flow sorted on a Mo-Flo XDP.
Preparation of a genomic DNA library for phenotypic analyzes
DNA from migration and phagocytosis assays was quantified using a Qubit fluorometer. NEBNext Ultra II FS libraries with Dual Index Primer Set 1 were quality controlled by Qubit, BioAnalyser or TapeStation and/or KAPA qPCR, multiplexed and sequenced on an Illumina NovaSeq 6000.
Cas9-guide all-in-one vector cloning
Three guide pairs per target and intergenic controls were array cloned into an all-in-one vector. The sequences are listed in Supplementary Table 16 and the library can be made available upon request.
Primers containing the 5′ or 3′ guide were used to amplify the sgRNA backbone-tRNA region by PCR with Q5 High-Fidelity 2X Master Mix in an array format to generate the dgRNA cassette.62. The purified PCR products were cloned by Gibson assembly into BsmBI-v2-digested pLentiCRISPR v3.0 and transformed into DH5-α cells. Colonies were selected and verified by Sanger sequencing. The arrayed clones were pooled and expanded into electrocompetent cells. MiSeq verification of guide distribution was performed after nested PCR with KAPA HiFi HotStart ReadyMix with 12 cycles of 98°C for 20 s, 60°C for 15 s, and 72°C for 15 s. PCR1 was purified on column and 1/100 of the purified product was used as template for PCR2, with 14 cycles at 98°C for 20 s, 70°C for 15 s, and 72°C for 15 s.
Production of lentiviral particles
Lenti-X HEK293T cells (14 × 106 cells) at approximately 70% confluence were transfected with 7.5 µg of pSIV3+ or library, 18.5 µg of psPAX2 and 4 µg of pMD2.G using Lipofectamine LTX. The virus collected at 48 h and 72 h was centrifuged, filtered (0.45 μm), concentrated to 20,000g for 3 h at 4°C, resuspended in 1.5% BSA/DPBS and frozen at −80°C according to previously published methods73.
Total protein extraction and Western blotting
Day 14 cells were lysed in RIPA buffer. Protein quantified by BCA (10 to 40 μg) was reduced, boiled, and analyzed on 4 to 15% Mini-PROTEAN TGX gels at 100 V for 75 min, then transferred to PVDF at the same parameters. Blocked membranes received primary antibodies overnight at 4°C, followed by HRP-conjugated secondary antibodies for 1 h before chemiluminescent imaging. Densitometry values were normalized to maintenance and untreated controls to determine “relative protein expression (to control).”
CRISPR KO screening for phagocytosis
Human KOLF2.1S iPSCs were differentiated into iMGL as described above. The library contained 783 all-in-one dual-guide CRISPR vectors targeting 250 priority AD GWAS genes and 30 intergenic controls (“NeuroKO”).7,14,52. The gRNA pairs were designed using docking guides chosen from MinLib74 and paired with guides targeting the same exon using a tRNA-based dual guide system62. Precursors were transduced at a multiplicity of infection between 1.2 and 1.5 with a viral accessory protein (VPX) to improve transduction efficiency in this model75. We performed three biological replicates of the screen.
After terminal differentiation into iMGL for 14 days, iMGLs were incubated with pmChGIP SH-SY5Y for 6 h. Non-phagocytosed cargo was washed, iMGLs lifted and fixed with 2% paraformaldehyde before being sorted on the mCherry signal into four bins: top 20%, 55–75% (upper middle), 25–45% (lower middle) and bottom 20%. The dgRNA sequences were amplified and indexed by PCR and sequenced by Illumina NovaSeq. After deconvolution, the gRNA sequences were quantified by MAGeCK76. Mapping effectiveness and guide representation, assessed using the Gini index, were examined with MAGeCKFlute77 to confirm the quality of the data, and are presented in Fig. 23 additional. After this step, guide overrepresentation was calculated between the bottom 20% and top 20%, representing the lowest and highest phagocytic iMGLs. The full methodology has already been published73.
Networked lentiviral screening
The AOWH_2, HEGP_3, and KOLF2.1S lines from the HipSci repository (www.hipsci.org) were used for all CRISPR screening validations. Three TREM2 and three intergenic sgRNAs were cloned, produced, titrated with resazurin, and pooled. Precursors on days 36, 40 and 46 received 4 μg ml-−1 polybrene under wild-type, VPX control, TREM2 virus, or intergenic virus conditions. The medium was replaced after 24 h and 1 µg ml−1 puromycin was added on days 3 or 4, with half changes on days 7 and 10. TREM2/vinculin Western blotting on day 14 and pmChGIP SH-SY5Y flow cytometry at 6 hours were used to assess inactivation and phagocytosis, respectively.
TREM2 ASO reversed
An overview of the ASO experiments is provided in Supplementary Figure 22. TREM2-171, TREM2-192, Scramble 1, and Scramble 2 ASO sequences.71 (Supplementary Table 16) were applied to KOLF2.1S precursors on day 7 at triplicate doses ranging from 20 μM to 76.3 pM. Proteins were collected on day 14. Half-maximal inhibitory concentration (IC50) and an inhibitory concentration of 90% (IC90) values were calculated in R using the drm() function from the drc package (v.3.0-1)78 (Supplementary Fig. 22). For validation experiments, the above protocol was repeated at the respective IC.50 and IC90 doses for TREM2-171 and TREM2-192, with scrambling controls corresponding to the respective IC doses for each ASO targeting TREM2.
AOWH_2, HEGP_3 and KOLF2.1S were used as follows. Day 36, 40, and 46 precursors were plated at 4.84 × 105 cells per ml in 48-well plates. ASO was added on day 7, with mid-range changes on days 3 or 4 and day 10, and testing on day 14. TREM2/vinculin Western blotting and 6 h pmChGIP SH-SY5Y flow cytometry were used to measure protein and phagocytosis relative to vehicle.
Genotype imputation and quality control
Genotyping table files from the HipSci (http://www.hipsci.org) and IPMAR projects19 were imputed using the eQTL catalog from the genimpute pipeline79. Post-imputation quality control retained variants with imputation r20.4 and MAF 0.01. Sex was imputed for donors with bcftools +guess-ploidy on region 2,781,480 to 155,701,381 of the X chromosome.
Deconvolution of the proportion of donors by WGS
We have developed poodleR, an R library…
Gn Health
